Interferon-alpha in tumor immunity and immunotherapy

被引：284

作者：

Belardelli, F

Ferrantini, M

Proietti, E

Kirkwood, JM

机构：

[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy

[2] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2002年 / 13卷 / 02期

关键词：

interferon-alpha; tumor; immunity; immunotherapy;

D O I：

10.1016/S1359-6101(01)00022-3

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interferon-alpha (IFN-alpha) is a pleiotropic cytokine belonging to type I IFN, currently used in cancer patients. Early studies in mouse tumor models have shown the importance of host immune mechanisms in the generation of a long-lasting antitumor response to type I IFN. Recent studies have underscored new immunomodulatory effects of IFN-alpha including activities on T and dendritic cells, which may explain IFN-induced tumor immunity. Reports on new immune correlates in cancer patients responding to IFN-alpha represent additional evidence on the importance of the interactions of IFN-a with the immune system for the generation of durable antitumor response, This knowledge, together with results from studies on genetically modified tumor cells expressing IFN-alpha, suggest novel strategies for using these cytokines in cancer immunotherapy and in particular the use of IFN-alpha as an immune adjuvant for the development of cancer vaccines. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：119 / 134

页数：16

共 107 条

[1] INTERFERONS IN THE THERAPY OF SOLID TUMORS
AGARWALA, SS
KIRKWOOD, JM
[J]. ONCOLOGY, 1994, 51 (02) : 129 - 136
[2] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs
Albert, ML
Sauter, B
Bhardwaj, N
[J]. NATURE, 1998, 392 (6671) : 86 - 89
[3] Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO
[4] 2-D
[5] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
Balch, CM
Soong, SJ
Gershenwald, JE
Thompson, JF
Reintgen, DS
Cascinelli, N
Urist, M
McMasters, KM
Ross, MI
Kirkwood, JM
Atkins, MB
Thompson, JA
Coit, DG
Byrd, D
Desmond, R
Zhang, YT
Liu, PY
Lyman, GH
Morabito, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
[6] Belardelli F, 1998, CANCER RES, V58, P5795
[7] INJECTION OF MICE WITH ANTIBODY TO INTERFERON RENDERS PERITONEAL-MACROPHAGES PERMISSIVE FOR VESICULAR STOMATITIS-VIRUS AND ENCEPHALOMYOCARDITIS VIRUS
BELARDELLI, F
VIGNAUX, F
PROIETTI, E
GRESSER, I
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (02): : 602 - 606
[8] The neglected role of type I interferon in the T-cell response: Implications for its clinical use
Belardelli, F
Gresser, I
[J]. IMMUNOLOGY TODAY, 1996, 17 (08): : 369 - 372
[9] ANTI-TUMOR EFFECTS OF INTERFERON IN MICE INJECTED WITH INTERFERON-SENSITIVE AND INTERFERON-RESISTANT FRIEND-LEUKEMIA CELLS .1.
BELARDELLI, F
GRESSER, I
MAURY, C
MAUNOURY, MT
[J]. INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (06) : 813 - 820
[10] ROLE OF INTERFERONS AND OTHER CYTOKINES IN THE REGULATION OF THE IMMUNE-RESPONSE
BELARDELLI, F
[J]. APMIS, 1995, 103 (03) : 161 - 179

← 1 2 3 4 5 6 7 8 9 10 →